Onconova Therapeutics, Inc. (ONTX)

Check out top investors' recommendation for ONTX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
N/A
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its products include Rigosertib intravenous (IV) that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); Rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and Rigosertib IV, a combination therapy with gemcitabine in a Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer. The company?s products also comprise ON 013105 that is in Phase I clinical trials to treat various lymphomas and leukemias; and Recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism; ON 108600, an inhibitor of cyclin-dependent kinase 9 and casein kinase 2; ON 044580, a dual inhibitor of janus kinase 2 and Bcr-Abl kinase; ON 24 series of compounds that are oral anti-tubulin agents; and ON 146 series, which are selective inhibitors of PI3K alpha/delta isoforms. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Joseph Pantginis Roth Capital Partners LLC Buy   Mar 26, '19     25.00  Mar 26, '20  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Feb 08, '19     25.00  Feb 08, '20  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 02, '19     25.00  Jan 02, '20  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Sep 27, '18     25.00  Sep 27, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Aug 14, '18     3.00  Aug 14, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Mar 01, '18     7.50  Mar 01, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 18, '18     6.00  Jan 18, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Dec 12, '17     6.00  Dec 12, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Nov 09, '17     6.00  Nov 09, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 09, '17     6.00  Oct 09, '18  N/A 
Jorge Aura Unaffiliated Buy   Feb 08, '16   4.40  1.00  Aug 08, '16  -24.09%